S2Medical wins procurement for wound healing equipment in Region Halland

Report this content

S2Medical has won a procurement in Region Halland for products within the Company’s wound healing segment. The agreement with Region Halland will commence on the 1st of April 2023 and last until the 31st of March 2026 whereafter it can be extended for an additional year. The Region has not yet communicated any specific order volume. Information about the expected order volume may be communicated at a later time. Region Halland reserves the right to add additional products to the tendered list during the validity of the agreement. Such additional products could be additional sizes or novel products within the same category that the Company can offer.

 

S2Medicals wound healing assortment consists of several products which facilitate in all phases of wound healing as well as contribute to a substantially improved quality of life for the patients and a reduced cost of care.

 

”We have for several years been delivering products within the scope of Regions Hallands procurement. The newly won procurement ensures the Regions access to our products for up to 5 years which also gives S2Medical a great possibility to grow within this Region which we see as a major win for us, the Region as well as the patient that are being treated there.” Says the Company’s CEO Petter Sivlér.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-03-2023 12:39 CET.

Contact Details
Petter Sivlér – CEO, S2Medical AB (publ)
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se

Certified Adviser
Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se 
E-mail: ca@vatorsec.se

About S2Medical 

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084

Subscribe

Documents & Links